Biotech is an industry that uses technology to create products that help people and the environment. It can include developing disease vaccines and improving agricultural processes to use less energy and more. Investing in biotechnology stocks is risky, but the rewards can be enormous. The best way to gain exposure is through a mutual fund or exchange-traded fund (ETF).

If you want to add a biotech stock to your portfolio, Amgen should be considered (NASDAQ: AMGN). The company creates novel human therapeutics for patients with serious diseases. Its products are based on advanced human genetics and aid in the discovery and understanding of disease mysteries.

Amgen has a track record of developing drugs that improve health outcomes and have a significant impact on people's lives. Its pharmaceutical operations are divided into six categories: inflammation, cancer/haematology, bone health, cardiovascular disease, neurological disorders, and nephrology.

Amgen's stock has risen 11.79% this year, outperforming the iShares Biotechnology ETF (NYSEARCA: IBB) by more than 31%. The stock has a solid 3.7% yield, making it an excellent choice for dividend growth investors.

Amgen has been involved in biotechnology for many years. Its products are built on cutting-edge gene editing technology. It is working on treatments for cystic fibrosis, Alzheimer's disease, Parkinson's disease, and haemophilia. Analysts believe the company has a bright financial future.

Ionis is a leading RNA-targeted drug discovery and development company dedicated to developing drugs for patients with the greatest unmet medical needs. It has a large pipeline of drugs that are either first-in-class or best-in-class and have the potential to be marketable and transform patient care.

Antisense technology, developed by Ionis, is an efficient, broadly applicable drug discovery tool that can be used to treat diseases where no other therapeutic approaches have worked. It has created several drugs that are now in the middle to late stages of development.

The company has a diverse portfolio of assets in various disease areas, the majority of which are in phase 3 development. Their ALS program is led by towers, which target superoxide dismutase 1 (SOD1) and is being prioritized for approval in 2023.

Tominersen, another powerful asset in the CNS, reduces the expression levels of mutated HTT in Huntington's disease. They also have a leading asset in triglyceride-driven disease, which lowers high triglyceride levels. They are also working on DNA-targeted therapies, a new type of treatment that involves editing genetic information.

Look no further than Exelixis if you're looking for a biotech company with a great stock price. This oncology leader focuses on developing new medicines for difficult-to-treat cancers. The company's headquarters are in Alameda, California. It has a campus-like setting with gardens, covered walkways, bike paths, and a ferry service.

Exelixis is working on a number of products, including the blockbuster cabozantinib. It is also a pioneer in antibody-drug conjugates, which are gaining popularity as alternatives to chemotherapy for cancer patients due to their low off-target effects and high cytotoxicity at tumour levels.

The company is currently testing XL092, a drug being developed for metastatic colorectal cancer. Colorectal cancer is the third leading cause of death in the United States, making this a good target. It's a disease that can be treated fairly well if caught early, but once it's spread, it can be extremely difficult to treat effectively.

Bristol-Myers Squibb discovers, develops, and markets pharmaceuticals for a variety of therapeutic areas, including oncology, immunology, cardiovascular disease, and haematology. Its products include chemically synthesized or small molecule drugs, as well as biologics, which are products produced through biological processes.

BMY has several drugs on the market, including the blood thinners Plavix and Eliquis, as well as the cancer medication Opdivo. These three products account for a sizable portion of Bristol-Myers Squibb's revenue and may face competition in the near future.

On the plus side, BMY has a robust drug candidate pipeline and is leveraging its substantial cash reserves to fund the development of new products. It is also a pioneer in immuno-oncology, and it is a member of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.

Aside from drug candidates, BMY has a diverse portfolio of commercial products with high sales. Among these are the blood thinner Plavix, the cancer drug Opdivo, and the antipsychotic Abilify. Meanwhile, its hepatitis C treatment Sovaldi has strong sales and a competitive pricing advantage over generics.

Go Back

Post a Comment
Created using the new Bravenet Siteblocks builder. (Report Abuse)